CTP‐543 for the Treatment of Adults with Moderate to Severe Alopecia Areata

Last Updated:
05/29/2019
Status:
Recruiting
Country:
United States
Eligibility:
Age 18-65; diagnosed with moderate to severe alopecia areata
Drug:
CTP‐543
Administration:
Oral
Sponsor: 
Concert Pharmaceuticals, Inc.

The purpose of this study is to compare the effectiveness and tolerability of two different dosing regimens of the investigational drug, CTP-543, in adults with chronic, moderate to severe alopecia areata. Approximately 60 adults with moderate to severe alopecia areata may participate in this study at clinical trial sites throughout the United States and Canada. If patients are eligible to participate in the study, a total time in the study will last up to 32 weeks (11 visits to the trial site), and up to 24 weeks on treatment.

If you or someone you know is interested in learning more about this clinical trial, please contact researchparticipant@innovaderm.com or AAclinicaltrial_inquiries@concertpharma.com. For a full description of the study and a listing of all trial site locations, please visit www.clinicaltrials.gov.